Lesson plan
EB-003
EB-003 is a non-hallucinogenic serotonin receptor agonist which is under development for the treatment of depressive disorders and anxiety disorders. It is a tryptamine and a derivative of the serotonergic psychedelic dimethyltryptamine (DMT). The drug acts as a non-selective agonist of serotonin receptors, including of the serotonin 5-HT 1A , 5-HT 1B , and 5-HT 2A receptors. It is not a serotonin 5-HT 2B receptor agonist. EB-003 produces psychoplastogenic effects. Due to targeting not only the serotonin 5-HT 2A receptor but also the serotonin 5-HT 1B receptor to influence neuroplasticity, EB-003 has been branded a new type of drug called a "neurostabilogen" by its developer. EB-003 is being developed by Enveric Biosciences. As of February 2025, it is in the preclinical research stage of development. A phase 1 clinical trial is being planned. The drug's exact chemical structure does not yet seem to have been disclosed. It has been patented, though the patent does not yet appear to have been published.
Article summary
EB-003 is a non-hallucinogenic serotonin receptor agonist which is under development for the treatment of depressive disorders and anxiety disorders. It is a tryptamine and a derivative of the serotonergic psychedelic dimethyltryptamine (DMT). The drug acts as a non-selective agonist of serotonin receptors, including of the serotonin 5-HT 1A , 5-HT 1B , and 5-HT 2A receptors. It is not a serotonin 5-HT 2B receptor agonist. EB-003 produces psychoplastogenic effects. Due to targeting not only the serotonin 5-HT 2A receptor but also the serotonin 5-HT 1B receptor to influence neuroplasticity, EB-003 has been branded a new type of drug called a "neurostabilogen" by its developer. EB-003 is being developed by Enveric Biosciences. As of February 2025, it is in the preclinical research stage of development. A phase 1 clinical trial is being planned. The drug's exact chemical structure does not yet seem to have been disclosed. It has been patented, though the patent does not yet appear to have been published.
Key claims
No claims recorded.
Discussion questions
- Summarise the article in your own words. Which single claim would you verify first, and why?
- Which claim in this article is most likely to be revised as the sources update? How would you check its current status?
- If two sources disagreed about one of these facts, what would you need in order to trust one over the other?
Bibliography
No sources recorded.
Key claims and bibliography are generated from the same tracked claims and sources as the article page.